Alto vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital pharmacy with same-day delivery and transparent price comparison; concierge mobile app experience competing with Amazon Pharmacy and Capsule for urban medication delivery.
About
Alto Pharmacy is a digital pharmacy providing prescription delivery service with a concierge pharmacy experience — offering same-day or next-day delivery of prescriptions to customers' homes, transparent pricing (showing the lowest cost option including GoodRx discounts, insurance, or cash pay), and dedicated pharmacist support through the Alto mobile app. Founded in 2015 by Mattieu Gamache-Asselin and Jamie Karraker in San Francisco, Alto has raised approximately $350 million and operates in major US markets including San Francisco, Los Angeles, New York, Houston, and Denver.\n\nAlto's model combines an app-based pharmacy experience with local courier delivery infrastructure — customers transfer their prescriptions to Alto, and a courier delivers medications within hours. The app shows real-time prescription status, communicates with pharmacists through chat, and automatically compares pricing across insurance, manufacturer coupons, and GoodRx discounts to ensure the customer pays the lowest price. Proactive refill management and automatic renewal outreach reduce the friction of managing chronic medications.\n\nIn 2025, Alto competes with Amazon Pharmacy (backed by Amazon's logistics and Prime), Capsule (acquired by NovaBay Pharmaceuticals), PillPack (Amazon), Walgreens and CVS app-based delivery for on-demand pharmacy delivery. The retail pharmacy market is consolidating — independent pharmacies face PBM reimbursement pressure and CVS/Walgreens have been closing unprofitable locations. Alto's model of app + courier delivery + price transparency resonates with urban tech consumers. The 2025 strategy focuses on expanding specialty pharmacy capabilities (high-cost biologics and specialty medications that require complex handling), growing in new geographic markets, and deepening integrations with healthcare providers for seamless prescribing-to-delivery workflows.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.